|
First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma.
Patients are now being enrolled in the U.S. for the Gamida Cell-Teva Joint Venture ExCell trial studying StemEx® as an alternative treatment for bone marrow transplants.
Jerusalem, Israel, (November 6, 2007) --- The Gamida Cell-Teva Joint Venture announced today that the first patient in the international, pivotal registration ExCell study has undergone a StemEx® transplant at the Ireland Cancer Center of University Hospitals Case Medical Center. StemEx® is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit.
The single arm, multi-center ExCell study will assess the efficacy and safety of the StemEx®transplantation as a treatment for hematological malignancies, including leukemia and lymphoma. The U.S. Food and Drug Administration (FDA) granted ExCella Special Protocol Assessment (SPA) in October 2006 and StemEx® orphan drug status in March 2005.
|